| Literature DB >> 34630777 |
D González-Martín1, J Álvarez-De la Cruz1, P Martín-Vélez1, J Boluda-Mengod1, J L Pais-Brito1,2, M Herrera-Pérez1,2.
Abstract
INTRODUCTION: The COVID-19 pandemic has led to the confinement of approximately one third of the world population, causing a drastic change in the activities of daily life with many repercussions at the health, economic and social levels.Entities:
Keywords: COVID-19; Fractures; Hospital stay; Traumatology
Year: 2020 PMID: 34630777 PMCID: PMC8148574 DOI: 10.1016/j.recot.2020.07.010
Source DB: PubMed Journal: Rev Esp Cir Ortop Traumatol ISSN: 1888-4415
Epidemiological analysis.
| Groups | p value | Total (n = 190) | ||
|---|---|---|---|---|
| Pre-confinement | Confinement | |||
| 13/1/20−13/3/20 | 14/3/20−13/5/20 | |||
| (n = 112) | (n = 78) | |||
| .116 | ||||
| Male | 56 (50%) | 48 (61.5%) | 104 (54.7%) | |
| Female | 56 (50%) | 30 (38.5%) | 86 (45.3%) | |
| Age | 65.4 (2–100) | 73 (4–98) | .007 | 68.5 (2–100) |
| .274 | ||||
| 0 | 18 (16.1%) | 19 (24.4%) | 37 (19.5%) | |
| 1 – 3 | 31 (27.7%) | 16 (20.5%) | 47 (24.7%) | |
| > 3 | 63 (56.3%) | 43 (55.1%) | 106 (55.8%) | |
| .654 | ||||
| Lower | 92 (82.1%) | 66 (84.6%) | 158 (83.2%) | |
| Upper | 20 (17.9%) | 12 (15.4%) | 32 (16.8%) | |
| .728 | ||||
| Left | 56 (50%) | 37 (47.4%) | 93 (48.9%) | |
| Right | 56 (50%) | 41 (52.6%) | 97 (51.1%) | |
| < .001 | ||||
| At home | 63 (56.3%) | 66 (84.6%) | 129 (67.9%) | |
| Public place | 49 (43.8%) | 12 (15.4%) | 61 (32.1%) | |
| .288 | ||||
| Low energy | 98 (87.5%) | 72 (92.3%) | 170 (89.5%) | |
| High energy | 14 (12.5%) | 6 (7.7%) | 20 (10.5%) | |
| Outpatient care | 9 (8%) | 10 (12.8%) | .279 | 19 (10%) |
| COVID-19 | 0 (0%) | 4 (5.1%) | .015 | 4 (2.1%) |
| Death | 7 (6.3%) | 3 (3.8%) | .465 | 10 (5.3%) |
Relevant comorbidities (diabetes, high blood pressure, heart failure, kidney disease, dementia, etc.).
Anatomical site of the fractures.
| Groups | p value | Total (n = 190) | ||
|---|---|---|---|---|
| Pre-confinement | Confinement | |||
| 13/1/20 - | 14/3/20−13/5/20 | |||
| 13/3/20 | (n = 78) | |||
| (n = 112) | ||||
| Anatomical site | .162 | |||
| Hip | 48 (42.9%) | 44 (56.4%) | 92 (48.4%) | |
| Femur | 8 (7.1%) | 6 (7.7%) | 14 (7.4%) | |
| Foot and ankle | 26 (23.2%) | 9 (11.5%) | 35 (18.4%) | |
| Hand, wrist, and forearm | 16 (14.3%) | 9 (11.5%) | 25 (13.2%) | |
| Humerus | 3 (2.7%) | 3 (3.8%) | 6 (3.2%) | |
| Clavicle | 1 (.9%) | 0 (0%) | 1 (.5%) | |
| Patella | 0 (0%) | 3 (3.8%) | 3 (1.6%) | |
| Tibia (plateau and diaphysis) | 6 (5.4%) | 3 (3.8%) | 9 (4.7%) | |
| Pelvis and acetabulum | 4 (3.6%) | 1 (1.3%) | 5 (2.6%) | |
General hospital stay.
| Groups | p value | Total (n = 162 | ||
|---|---|---|---|---|
| Pre-confinement | Confinement | |||
| 13/1/20−13/3/20 | 14/3/20−13/5/20 | |||
| (n = 96 | (n = 66 | |||
| Preoperative stay | 4.14 (SD 5.8) | 2.77 (SD 2.9) | .575 | 3.59 (SD 4.9) |
| Postoperative stay | 10.76 (SD 17.9) | 4.11 (SD 3.5) | .006 | 8.05 (SD 14.3) |
| Total hospital stay | 14.92 (SD 19.6) | 5.16 (SD 11.6) | < .001 | 11.64 (SD 15.9) |
SD: standard deviation.
Excluding outpatients and those treated conservatively.
Hospital stay of hip fractures.
| Hip fractures | p value | Total (n = 89 | ||
|---|---|---|---|---|
| Pre-confinement | Confinement | |||
| 13/1/20−13/3/20 | 14/3/20−13/5/20 | |||
| (n = 46) | (n = 43) | |||
| Preoperative stay | 3.3 (SD 5.9) | 2.6 (SD 2.1) | .512 | 2.97 (SD 4.5) |
| Postoperative stay | 11.98 (SD 12.5) | 4.47 (SD 3.3) | < .001 | 8.35 (SD 9.9) |
| Total hospital stay | 15.35 (SD 13.1) | 7.02 (SD 4.3) | < .001 | 11.37 (SD 10.7) |
SD: Standard Deviation.
Intracapsular, extracapsular and periprosthetic.
Excluding conservative treatment.
Site of injury in young adults (18–55a).
| Fractures in young adults
(18−55a) | p value | Total (n = 57) | ||
|---|---|---|---|---|
| Pre-confinement | Confinement | |||
| 13/1/20−13/3/20 | 14/3/20−13/5/20 | |||
| (n = 40) | (n = 17) | |||
| < 0,001 | ||||
| At home | 7 (17.5%) | 11 (64.7%) | 18 (31.6%) | |
| Public place | 33 (82.5%) | 6 (35.3%) | 39 (68.4%) | |
Figure 1Provincial map of IgG anti-SARS-CoV-2 antibodies according to the results of the seroprevalence study. ENE-COVID-National Centre for Epidemiology (ISC-III).